Differentiating neuroblastoma: a systematic review of the retinoic acid, its derivatives, and synergistic interactions.
A neuroblastoma (NB) is a solid paediatric tumour arising from undifferentiated neuronal cells. Despite the recent advances in disease management and treatment, it remains one of the leading causes of childhood cancer deaths, thereby necessitating the development of new therapeutic agents and regimens. Retinoic acid (RA), a vitamin A derivative, is a promising agent that can induce differentiation in NB cells. Its isoform, 13-cis RA or isotretinoin, is used in NB therapy; however, its effectiveness is limited to treating a minimal residual disease as maintenance therapy. As such, research focuses on RA derivatives that might increase the anti-NB action or explores the potential synergy between RA and other classes of drugs, such as cellular processes mediators, epigenetic modifiers, and immune modulators. This review summarises the in vitro, in vivo, and clinical data of RA, its derivatives, and synergising compounds, thereby establishing the most promising RA derivatives and combinations of RA for further investigation.
National Children’s Research Centre (project grant (A/17/2)
CommentsThe original article is available at https://www.mdpi.com
Published CitationBayeva N, Coll E, Piskareva O. Differentiating neuroblastoma: a systematic review of the retinoic acid, its derivatives, and synergistic interactions. Journal of Personalized Medicine. 2021;11(3):211.
Publication Date16 March 2021
- Anatomy and Regenerative Medicine
- School of Pharmacy and Biomolecular Sciences
- Biomaterials and Regenerative Medicine
- Immunity, Infection and Inflammation
- Published Version (Version of Record)